The Food and Drug Administration (FDA) added a neurological disorder warning to the Johnson and Johnson COVID-19 vaccine.
Guillain-Barré syndrome is a disorder that causes the body’s immune system to attack the nervous system. The vaccine label now warns, “reports of adverse events following use of the Janssen COVID-19 Vaccine under emergency use authorization suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination.”
The J&J vaccine is the only non-mRNA vaccine option currently on the market. In October of 2020, trials of Johnson and Johnson’s COVID-19 vaccine were temporarily paused due to an unexpected and unexplained illness in a study participant. In April, distribution was halted amid reported blood clotting in the brains of vaccinated individuals.
FBA reported, “On April 13, the FDA and CDC asked states to temporarily pause use of J&J’s vaccine ‘out of an abundance of caution’ following reports of the rare blood clots. Within hours of the warning, over a dozen states halted the use with the J&J vaccine.” Johnson & Johnson, Moderna, and Pfizer stand to make over 100 billion in revenue from COVID-19 vaccines.
By the end of 2021, J&J’s goal is to produce and distribute one billion doses globally, and make a profit of 10 billion dollars. Each dose of the single-shot vaccine is being sold to countries for 10 USD. The company has also made an agreement with the US: 100 million doses in exchange for $1B, along with the option of purchasing another 200 million doses, if necessary. Vaccine producers and distributors are not legally liable for adverse effects caused by their products.
ARTICLE: ANTOINETTE AHO
MANAGING EDITOR: CARSON CHOATE
PHOTO CREDITS: INDIAN EXPRESS
Latest posts by Antoinette Aho (see all)
- House Democrats block Iron Done money from government funding bill - September 27, 2021
- DHS temporarily suspends use of horse units in Del Rio amid backlash - September 27, 2021
- New York City to enforce $50 fines for maskless transit riders - September 27, 2021